Formycon Signs a Licence Agreement with ATHOS to Acquire Assets for FYB202 (biosimilar, ustekinumab) & FYB201 (biosimilar, ranibizumab)
Shots:
- Formycon acquires 100% of rights in FYB202 (biosimilar, ustekinumab), 50% stake of ATHOS in FYB201 (biosimilar, ranibizumab) & operational development unit Bioeq GmbH
- ATHOS to receive a total value of ~$685M incl. funds related to new shares & earn-out component in the future sales of Formycon generated with FYB201 & FYB202, Formycon’s shares were valued at $87.82. The transaction is expected to be close at mid-2022
- ATHOS will become the largest shareholder of Formycon with ~26.6% share capital. The acquisition of Bioeq enables Formycon to strengthen its development & accelerated pipeline with experienced experts from clinical development, regulatory affairs, business development & others
Ref: Formycon | Image: Formycon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
